MNKD
MANNKIND CORP
NASDAQ · Healthcare · Biotechnology · US
$3.54
−1.12%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.62
From 52W high−43.00%
Volume5.49M
Market cap$1.14B
P/E (TTM)—
P/S (TTM)2.9x
Div yield—
Key dataSep 18, 2026
Open
$3.62
From 52W high
−43.00%
Volume
5.49M
Market cap
$1.14B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
44.2x
P/E (TTM)
—
RSI (14)
35.7
MomentumView details →
1D Return
−1.12%
YTD Return
−38.02%
SummaryUpdated Jun 1, 2026
MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company founded in 1991 and headquartered in Westlake Village, California. The company has transformed from a single-product diabetes-focused entity into a diversified biopharmaceutical company with multiple revenue streams. MannKind specializes in developing and commercializing inhaled therapeutic products using its proprietary <b>Technosphere</b> drug delivery platform, primarily targeting endocrine disorders and orphan lung diseases. The company went public in 2004 and has evolved significantly over the past two decades, particularly accelerating its diversification strategy since 2022.
Similar companies
Latest newsMore news →
MannKind and Rose Pharma Inc entered a licensing and collaboration agreement to develop an inhaled rapid-acting, short-duration GLP-1 for weight management, combining Rose Pharma's investigational GLP-1 receptor agonist with MannKind's Technosphere inhalation technology.11d agoMannKind Corp reported Q2 2026 total revenue of $109.4 million, up 43% year-over-year, with a net loss of $19.1 million, driven by strong sales of Afrezza and Furoscix.47d ago